Review Article
Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis
Table 3
Relationship between low expression of p16 and other prognostic factors in patients with bladder cancer.
| | Author | Year | Nation | No. (M/F) | Age | Stage | Grade | Cut-off value | Other related biomarkers | Measuring method | Antibody source (dilution) | Outcome | value |
| |
Jin et al. [24] | 2006 | USA | 39 (25/14) | 65 (42–84) | T2–T4 | G1–G4 | 10% | P53, pRB | Immunohistochemistry | NR (1 : 50) | OS/PFS (2-year survival) | 0.001 | <0.001 | | |
Tzai et al. [25] | 2004 | China (Taiwan) | 65 (44/21) | 61.5 (41–84) | T2–T4 | G2-G3 | Score = 4 | P53, pRB | Immunohistochemistry | Santa Cruz (1 : 20) | PFS/DSS | 0.74 | 0.49 | | |
Yurakh et al. [6] | 2006 | Spain | 55 | NR | Ta–T4 | G1–G3 | 10% | 9p21 (P14, P15, P16) | Immunohistochemistry | Santa Cruz (1 : 500) | RFS/OS/PFS (3-year survival) | 0.31 | 0.022 | 0.012 |
|
|
M: male; F: female; RFS: recurrence-free survival; OS: overall survival; PFS: progression-free survival; DSS: disease-specific survival; NR: not reported; No.: number of patients.
|
